Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases

Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases

BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively wit...

Full description

Saved in:
Bibliographic Details
Main Author: Ribero, David (author)
Other Authors: Wang, Huamin (author), Donadon, Matteo (author), Zorzi, Daria (author), Thomas, Melanie B. (author), Eng, Cathy (author), Chang, David Z. (author), Curley, Steven A. (author), Abdalla, Eddie K. (author), Ellis, Lee (author), Vauthey, Nicolas (author)
Format: article
Published: 2007
Online Access:http://hdl.handle.net/10725/2578
http://dx.doi.org/10.1002/cncr.23099
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.23099
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://hdl.handle.net/10725/2578
http://dx.doi.org/10.1002/cncr.23099
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.23099

Similar Items